← Back to Search

CAR T-cell Therapy

BPX-601 for Prostate Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Bellicum Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through phase 1 completion, up to 5 years
Awards & highlights

Summary

This trial is testing a new cancer treatment where patients' T cells are modified to target and attack cancer cells with the protein marker PSCA.

Eligible Conditions
  • Metastatic Castration Resistant Prostate Cancer
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through phase 1 completion, up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and through phase 1 completion, up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose Limiting Toxicity
Maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
Therapeutic procedure
Secondary outcome measures
Antitumor activity of BPX-601
Pharmacodynamics (PD) of BPX-601

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2: Phase 2 Dose ExpansionExperimental Treatment2 Interventions
Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 at the recommended cell dose level followed by one or more intravenous infusions of rimiducid.
Group II: Arm 1: Phase 1 Dose EscalationExperimental Treatment2 Interventions
Participants with advanced prostate cancer will receive an intravenous infusion of BPX-601 followed by one or more intravenous infusions of rimiducid. Dose escalation of BPX-601 will continue until the recommended cell dose level is reached.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rimiducid
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Bellicum PharmaceuticalsLead Sponsor
27 Previous Clinical Trials
1,201 Total Patients Enrolled
~20 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top